Prime Medicine PRME Business Segments — Research costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept prme:ResearchAndDevelopmentExpenseResearchCosts.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's business segments — research costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's business segments — research costs?
- Prime Medicine (PRME) reported business segments — research costs of $7.26M in Q1 2026.
- How has Prime Medicine's business segments — research costs changed year-over-year?
- Prime Medicine's business segments — research costs decreased by 34.2% year-over-year, from $11.04M to $7.26M.
- What is the long-term trend for Prime Medicine's business segments — research costs?
- Over 2 years (2023 to 2025), Prime Medicine's business segments — research costs has grown at a -22.9% compound annual growth rate (CAGR), from $59.61M to $35.45M.
- What does business segments — research costs mean?
- Represents the expenditures dedicated to research and development activities within a specific business segment, aimed at discovering or advancing new technologies and products. This metric is critical for biotechnology companies, as it reflects the level of investment in the innovation pipeline and future growth potential. High spending in this area indicates a commitment to long-term product development and technological leadership.